My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking

Glaxosmithkline Pharma Ltd Research Report - 09th Nov 2016

Pharmaceutical | Published on Nov 09th 2016


For 2QFY2017, sales stood at Rs783cr vs. Rs700cr expected and vs. Rs700cr in 2QFY2016, a yoy growth of 11.8%. On the operating front, the OPM came in at 15.9% vs. 17.2% in 2QFY2016 and vs. 17.0% expected. The company’s OPM was impacted by other expenses, which grew by 40.5% yoy. Thus, the company posted an Adj. net profit of Rs98cr vs. Rs101cr in 2QFY2016, a yoy de-growth of 2.9%. We maintain our Neutral rating on the stock.

Download Full Report


CMP 2,719
Target Price
Investment Period12 Months

Stock Info

MCAP BSE (Rs in Cr)Array
MCAP NSE (Rs in Cr)Array
P/E (x)Array
EPS (Rs.)Array
BV (Rs.)Array
Div Yield (%)Array
FV (Rs.)Array
P/BV (x)Array
EV/Sales (x)Array
EV/EBITDA (x)Array

Shareholding Pattern (%)

Public & Others12.0
Grand Total100.0

Trade Securely


Portfolio Tracking & Trading Application View Demo